Please login to the form below

Not currently logged in
Email:
Password:

Valeant adds Jeffrey Ubben to board

CEO of ValueAct supports takeover of Allergan

Valeant adds Jeffrey Ubben to boardValeant has appointed Jeffrey Ubben, CEO of ValueAct Capital, as a member of its board of directors.

Ubben joins at a crucial time for Valeant as the company tries to take over Allergan, the marketer of Botox and other aesthetic and health products.

The company will benefit from Ubben's rich business experience, which includes founding the investment management firm ValueAct Capital.

Ubben commented on the recent attempts to acquire Allergan, which have prompted a backlash, with Allergan questioning Valeant's business model.

“Valeant has become significantly undervalued on a standalone basis due to recent unjustified attacks on the company,” said Ubben. “We are strongly supportive of the Allergan-Valeant combination in light of their perfect strategic fit and the potential to create enormous shareholder value for both companies.”

2nd October 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

What are you doing, Dave?
Artificial Intelligence (AI) is invading all areas of healthcare. Is it our saviour or our nemesis?...
Fake News is Bad for your Health
Ill informed patients make poor health decisions...
Secrets of Pharma Advertising
If the goal of branding is to be different, why do so many Pharma brand ads look the same?...

Infographics